

1 **Diazepam attenuates the effects of cocaine on locomotion, 50-kHz ultrasonic vocalizations**
2 **and phasic dopamine release in the nucleus accumbens of rats**

3 William N. Sanchez^{1,2}, Jose A. Pochapski¹, Leticia F. Jessen¹, Marek Ellenberger³, Rainer K.
4 Schwarting³, Donita L. Robinson⁴, Roberto Andreatini¹, Claudio Da Cunha^{1,2}

5 ¹Laboratório de Fisiologia e Farmacologia do Sistema Nervoso Central, Department of
6 Pharmacology, Universidade Federal do Paraná, Curitiba, PR 81.530-980, Brazil

7 ²Department of Biochemistry, Universidade Federal do Paraná, Curitiba, PR 81.530-980,
8 Brazil.

9 ³Behavioral Neuroscience, Experimental and Biological Psychology, Faculty of Psychology,
10 Marburg Center for Mind, Brain and Behavior (MCMBB), Philipps-University of Marburg,
11 35032 Marburg, Germany.

12 ⁴Department of Psychiatry and Bowles Center for Alcohol Studies, University of North
13 Carolina, Chapel Hill, NC 27599-7178, United States.

14

15 **Correspondence**

16 Claudio Da Cunha, Laboratório de Fisiologia e Farmacologia do Sistema Nervoso Central,
17 Department of Pharmacology, Universidade Federal do Paraná, Curitiba, PR, Brazil. Email:
18 dacunha.claudio@gmail.com

19

20 **Funding information**

21 Coordination for the Improvement of Higher Education Personnel – Brazil (CAPES) – Finance
22 Code protocol 88881.198683/2018-01 and by The Brazilian National Council for Scientific
23 and Technological Development (CNPq) grant process number 432061/2018-5.

24

25 **Abbreviations:** NAc, nucleus accumbens; VTA, ventral tegmental area; FSCV, fast scan cyclic
26 voltammetry; USV, ultrasonic vocalizations.

27 **Abstract**

28 **Background and Purpose**

29 Currently, no effective drug exists to treat cocaine use disorders, which affect millions of
30 people worldwide. Benzodiazepines are potential therapeutic candidates, as microdialysis
31 and voltammetry studies have shown that they can decrease dopamine release in the
32 nucleus accumbens of rodents. In addition, we have recently shown that diazepam blocks
33 the increase in dopamine release and the affective marker 50-kHz ultrasonic vocalizations
34 (USV) induced by DL-amphetamine in rats.

35 **Experimental Approach**

36 Here we tested whether administration of $2.5 \text{ mg}\cdot\text{kg}^{-1}$ diazepam (i.p.) in adult male Wistar
37 rats could block the effects of $20 \text{ mg}\cdot\text{kg}^{-1}$ cocaine (i.p.) on electrically evoked phasic
38 dopamine release in the nucleus accumbens measured by fast-scan cyclic voltammetry, as
39 well as 50-kHz USV and locomotor activity.

40 **Key Results**

41 Cocaine injection increased evoked dopamine release up to 3-fold within 5 min and the
42 increase was significantly higher than baseline for at least 90 min. The injection of diazepam
43 15 min later attenuated the cocaine effect by nearly 50% and this attenuation was
44 maintained for at least 30 min. Stimulant drugs, natural rewards and reward predictive cues
45 are known to evoke 50-kHz USV in adult rats. In the present study, cocaine increased the
46 number of 50-kHz USV of the flat, step, trill, and mixed kinds by 12-fold. This effect was at
47 maximum 5 min after cocaine injection, decreased with time and lasted at least 40 min.
48 Diazepam significantly blocked this effect for the entire duration of the session. The distance
49 travelled by control rats during a 40-min session of exploration in an open field was at
50 maximum in the first 5 min and decayed progressively until the end of the session. Cocaine-
51 treated rats travelled significantly longer distances when compared to the control group,
52 while diazepam significantly attenuated cocaine-induced locomotion by up to 50%.

53 **Conclusions and implication**

54 These results suggest that the neurochemical, affective, and stimulant effects of cocaine can
55 be mitigated by diazepam.

56 **What is already known**

- 57 • Diazepam decreases dopamine release in the rodent nucleus accumbens (NAc) and
58 reduces some effects produced by DL-amphetamine.

59 **What this study adds**

- 60 • Diazepam attenuated the increase in phasic dopamine release caused by cocaine.
- 61 • Diazepam blocked the effect of cocaine on 50-kHz USV and locomotor activity.

62 **Clinical significance**

- 63 • This study demonstrates that diazepam can block specific effects of cocaine that
64 likely contribute to addiction.

65 **Key words:** Psychostimulants, benzodiazepines, drug dependence, addiction

66 **1 INTRODUCTION**

67 Although cocaine use disorders are a global epidemic problem that is growing in many parts
68 of the world, there is no FDA approved pharmacological treatment for this disorder (Farrell
69 et al., 2019; Kampman, 2019, UNODC 2020). Thus, it is urgent to find an effective and safe
70 pharmacotherapy to treat cocaine and amphetamine use disorders.

71 Cocaine binds to the dopamine transporter, limiting protein movement and acting as a
72 dopamine transporter blocker (Wang et al., 2015). Due to this interaction, cocaine causes an
73 increase in extracellular dopamine levels in the dorsal and ventral striatum (Church et al.,
74 1987; Hernandez and Hoebel, 1988; Garris and Wightman, 1995; Heien et al., 2005). The
75 increase in the intensity and frequency of dopamine release in the nucleus accumbens (NAc)
76 caused by cocaine reinforces self-administration of this drug and increases locomotor
77 activity in rodents and humans (Tilley et al., 2007; Hall et al., 2009). 50-kHz USV emitted by
78 adult rats in rewarding situations or in response to cues with incentive salience are also
79 evoked by cocaine and other stimulants in adult rats (Simola et al., 2012a, 2014). In

80 addition, sensory cues paired with cocaine acquires incentive salience and later can elicit
81 dopamine release causing drug-seeking behaviors (Phillips et al., 2003). Therefore, it is
82 possible that blocking the cocaine amplification of dopamine release can be a strategy to
83 block the rewarding and motivational effects of this drug (German et al., 2015; Volkow et
84 al., 2017).

85 Diazepam is a benzodiazepine used to treat anxiety, alcohol withdrawal, skeletal muscle
86 spasm and convulsive disorders (Calcaterra and Barrow, 2014). Diazepam binds to an
87 allosteric site in the GABA_A receptor (GABA_A-R), augmenting the activity of the gamma-
88 aminobutyric acid (GABA) transmission (Zhu et al., 2018; Masiulis et al., 2019) by enhancing
89 the GABA-A receptor affinity for GABA and subsequently increasing the channel-open
90 frequency (Uusi-oukari and Korpi, 2010). Diazepam has been shown to promote cocaine
91 abstinence (Augier et al., 2012) and to attenuate the stimulant locomotor effect of
92 morphine and amphetamine (Panhelainen et al., 2011). Also, we previously reported that
93 diazepam blocks the increase in phasic dopamine release in the mouse NAc and rat 50-kHz
94 USV, both evoked by amphetamine (Gomez-A et al., 2017; Guaita et al., 2018). As both
95 amphetamine and cocaine increased dopamine release, it is likely that diazepam will
96 similarly affect cocaine-induced dopamine release. However, as mentioned above, the
97 mechanisms by which amphetamines and cocaine increase dopamine release are not
98 identical. Therefore, in the present study we tested the hypothesis that diazepam blocks the
99 effect of cocaine on dopamine release. Here we used *in vivo* fast scan cyclic voltammetry
100 (FSCV) to show that diazepam can mitigate the increase in the electrically evoked phasic
101 dopamine release in the rat NAc. We also show that diazepam attenuated the increase in
102 the number of rat 50-kHz USV and the increase in locomotion observed in rats treated with
103 cocaine.

104 **2 METHODS**

105 **2.1 Animals**

106 Adult male Wistar rats (n=31 for FSCV, n=41 for USV) were housed in groups of five in
107 polypropylene cages (41 cm × 34 cm × 16 cm) with sawdust bedding under a 12 h/ 12 h
108 light/dark cycle (lights on at 7:00 a.m.) and a controlled temperature (22 ± 2 °C). Food and

109 water were available *ad libitum*. Males were used to better compare to previous studies
110 (Gomez-A et al., 2017, Guaita et al., 2018). All procedures were in accordance with the
111 National Institutes of Health Guide for the Care and Use of Laboratory Animals and
112 approved by the institutional Ethics Committee for Animal Experimentation of the
113 Universidade Federal do Paraná (Protocol 1157) consistent with Brazilian law (Bil#11.794/8
114 October 2008).

115 **2.2 Chemicals and solutions**

116 All chemicals were purchased from Sigma Aldrich (St Louis, MO), except for cocaine HCl
117 (donation from Curitiba Police Department inquiry # 5016610-91.2019.4.04.7000/PR).
118 Cocaine was 98% pure, as determined by nuclear magnetic resonance. Cocaine HCl was
119 dissolved in saline (0.9 % w/v) to 20.0 mg·mL⁻¹ and diazepam was dissolved in the vehicle
120 solution (2% propylene glycol, 8 % ethyl alcohol, using 5% sodium benzoate and benzoic acid
121 as buffers, and 2% benzyl alcohol, pH= 7.4) to 5 mg·mL⁻¹.

122 **2.3 *In vivo* Fast Scan Cyclic Voltammetry**

123 Animals were anesthetized with urethane (1.5 mg·kg⁻¹ i.p.) and placed in a stereotaxic frame
124 (David Kopf Instruments, Tujunga, CA). Urethane was used because there is no effect on
125 dopamine clearance *in vivo* (Garris et al., 2002; Sabeti et al., 2003). A stimulation electrode
126 (Plastics One, Roanoke, VA, USA, polished tips, 1 mm apart) was implanted in the ventral
127 tegmental area (VTA) (AP= - 0.52, ML= + 0.10, DV= - 0.82) and a carbon-fiber electrode (10-
128 80 µm length, 7 µm diameter, Goodfellow, Huntingdon, England) was implanted in the NAc
129 (AP= + 0.19, ML= + 0.14, DV= - 0.64) according to a rat brain atlas (Paxinos and Watson,
130 1998). An Ag/AgCl reference electrode was placed in the contralateral hemisphere and
131 affixed with dental cement.

132 The parameters of electrical stimulations and neurochemical recordings were as previously
133 described (Gomez-A et al., 2017) with some modifications. In brief, every 100 ms, a
134 triangular waveform potential (-0.4 V to +1.3 V to -0.4 V vs Ag/AgCl) was applied at a rate
135 of 400 V/s. After 30 min of waveform application to condition and stabilize the electrode,
136 trains of 35 biphasic pulses (0.5 ms per pulse, 600 µA, 60 Hz, 24 pulses) were applied to the
137 stimulating electrode every 300 s with a programmable optical isolator pulse generator

138 (MINCS, Mayo Investigational Neuromodulation Control System, Mayo Clinic). FSCV
139 measurements were recorded with a Wireless Instantaneous Neurotransmitter
140 Concentration Sensor system (WINCS, Mayo Clinic) and processed with the WINCS and
141 MINCS software (version 2.10.4.0, Mayo Clinic). Five trains of electrical pulses were applied
142 to confirm the stability of the FSCV recording. Then, another six trains of pulses were
143 applied (300 s apart) and the evoked currents were taken as baseline, given that the evoked
144 dopamine release did not vary by more than 16%. Immediately thereafter, rats received
145 cocaine (20.0 mg·kg⁻¹) or saline and another five trains of pulses were applied. Next,
146 diazepam (2.5 mg·kg⁻¹) or vehicle was administered and electrochemical data acquisition
147 continued for 70 min with electrical stimulation every 300 s.

148 The background-subtracted cyclic voltammograms were obtained by subtracting
149 voltammograms collected during stimulation from those collected up to 2 s before the
150 stimulation. Voltammetric responses were displayed as pseudo-color plots with the abscissa
151 as the voltage, the ordinate as the acquisition time, and the current encoded in color.
152 Temporal responses were determined by monitoring the current at the peak oxidation
153 potential for dopamine in successive voltammograms. To estimate dopamine concentration,
154 the recording electrodes were calibrated using a flow-cell (dopamine solution of 20 μM in
155 TRIS buffer) and the calibration factor was 1nA = 1.033 ± 0.407 μM. To confirm the identity
156 of the evoked dopamine release, background-subtracted cyclic voltammograms of the *in*
157 *vivo* electrochemical signal immediately after stimulation were averaged and correlated
158 with voltammograms from the *in vitro* calibration ($R^2=0.963$, $p < 0.001$).

159 **2.4 Histology**

160 After FSCV recording, rats were decapitated and brains were fixed in 4% formaldehyde for
161 10 days. Coronal slices of 50 μm were obtained using a vibratome (VT 1000S, Leica
162 Biosystems), stained with thionine, and compared to the rat atlas of Paxinos and Watson
163 (1998) to locate the electrodes' track.

164 **2.5 Ultrasonic vocalizations and locomotor activity.**

165 Animals were divided in four groups that received: (i) saline and the vehicle; (ii) saline and
166 diazepam (2.5 mg·kg⁻¹ dissolved in vehicle); (iii) vehicle and cocaine (20.0 mg·kg⁻¹ dissolved

167 in saline); (iv) cocaine (20.0 mg·kg⁻¹) and diazepam (2.5 mg·kg⁻¹). Rats were tested in two
168 sessions: baseline and treatment, 40 min each, 24 h apart. Drugs were administered only
169 immediately before the treatment session. In each session, each animal was gently placed
170 into an acrylic box (40 × 40 × 40 cm) with fresh sawdust bedding on the floor. USV were
171 recorded using a microphone (UltraSoundGate Condenser Microphone, CM16; Avisoft
172 Bioacoustics, Berlin, Germany) placed in the center and 25 cm above the floor of the box,
173 controlled by the Avisoft Recorder 2.7 software. USV 50-kHz calls were counted and
174 classified using DeepSqueak 2.6.1 software (Coffey et al., 2019). The videos recorded during
175 USV sessions were used to measure locomotor activity using automatized analysis with
176 EthoVision® XT software (Noldus, Wageningen, Netherlands).

177 **2.6 Statistics**

178 We applied the D'Agostino & Pearson and Shapiro-Wilk tests of normal distribution.
179 Variability among rats due to differences in electrode location and length was reduced by
180 using the equation “ $Y = [I_i/I_{BL}] * 100$ ”, where I_i is the oxidation current on time i , and I_{BL} is the
181 baseline evoked dopamine release. In each rat, the I_{BL} was calculated by averaging the
182 heights of the first 6 peaks of I_i recorded after the oxidation current values had stabilized
183 (see 2.3 for details). As neither raw data nor the transformed data passed the tests of
184 normal distribution, we used a generalized linear regression (GLM) model with Poisson-
185 distribution, link log function and Wald chi-square comparisons to test time and drug
186 effects. When appropriate, Sidak post hoc tests were used to compare differences among
187 groups. We used odds ratios and confidence intervals to describe the magnitude of
188 differences between groups and times.

189 The total number of USV calls (number of calls) did not pass the D'Agostino & Pearson and
190 Shapiro-Wilk tests of normal distribution. However, after transformation with the algorithm
191 [$Y = \sqrt{Y}$], they passed these tests of normal distribution and were analyzed by two-way
192 ANOVA with multiple comparisons and repeated measures, followed by the Tukey test to
193 measure differences between baseline and treatment for each group.

194 Locomotion scores over time passed the normal distribution tests and were analyzed by
195 repeated measure ANOVA followed by the Tukey test. The Poisson GLM was performed by

196 using SPSS statistic software (IBM SPSS Statistics for Windows, Version 26.0. Armonk, NY:
197 IBM Corp.). All the other analyses were done using GraphPad Prism software (San Diego,
198 CA). The 5 min-bin graphs of FSCV were made using Python (Python Software Foundation.
199 Python Language Reference, version 3.7, Amsterdam, Netherlands) and the other graphs
200 were made using GraphPad Prism software. Differences among groups were considered
201 significant if $p < 0.05$.

202 **3 RESULTS**

203 **3.1 Diazepam attenuated the cocaine effect on the phasic release of dopamine in the NAc**

204 To evaluate whether i.p. injection of diazepam blunted the effect of cocaine on phasic
205 dopamine release, we compared evoked dopamine release in three groups of rats:
206 cocaine+diazepam, cocaine+vehicle, and saline+vehicle (Figure 1a). The placements of the
207 stimulating electrodes in the VTA and the recording electrodes in the NAc were confirmed
208 (Figure 1b). Cocaine increased electrically evoked dopamine release, an effect that persisted
209 for at least 75 min and was attenuated by diazepam (Figure 1c). The generalized linear
210 model yielded significant main effects of group (Wald chi-square 1663.2, $df=2$, $p < 0.001$) and
211 time (Wald chi-square 987.6, $df=3$, $p < 0.001$), as well as a significant interaction of group by
212 time (Wald chi-square 765.6, $df=6$, $p < 0.001$). Thus, we compared parameter estimates
213 within groups across time points and between groups at each time point (see Figure 1c for
214 post-hoc comparisons). Evoked dopamine in the saline+vehicle group did not differ across
215 the experiment. In contrast, dopamine release in the cocaine+vehicle and
216 cocaine+diazepam groups increased similarly after cocaine injection (0-25 time bin). While
217 the cocaine+vehicle group continued to exhibit high levels of evoked dopamine release at
218 each post-cocaine time bin, administration of diazepam in the cocaine+diazepam group
219 significantly reduced this cocaine effect on dopamine release. Figure 1d shows
220 representative examples of voltammograms and color plots taken from one rat. Note that
221 after the electrical stimulation, current increased only in the potentials near the optimal
222 dopamine oxidation potential. These examples also illustrate that, at the dopamine
223 oxidation potential, the evoked current increase was higher after cocaine injection and
224 returned back to a lower level after the diazepam injection.

225 **3.2 Diazepam blocked the cocaine effect on 50 kHz USVs**

226 It is well established that psychostimulants produce an increase in appetitive USV in rats,
227 which can serve as index of positive affect (Simola et al., 2012a, 2014). Therefore, we
228 evaluated if diazepam would reduce such an effect (Figure 2). To address this question, we
229 placed adult male rats in an open field to record USV for 40 min on two days (Figure 2a). On
230 the first day we recorded basal USV (baseline day) and on the second day we recorded USV
231 under the effect of diazepam, cocaine, and saline+vehicle treatments at the same doses as
232 used in the FSCV experiment. A repeated measures ANOVA showed a significant session
233 factor ($F_{1,36} = 23.08$, $p < 0.001$), a significant group factor ($F_{3,36} = 6.32$, $p < 0.01$) and a
234 significant interaction between these factors ($F_{3,36} = 13.29$, $p < 0.001$). No significant
235 differences among groups were detected on the baseline day (data not shown). We used
236 Tukey test in all post-hoc comparisons among groups. On the test day, only animals that
237 received cocaine presented an increase in the 50-kHz USV compared with the other groups
238 ($p < 0.001$) and compared to the baseline day ($p < 0.001$). Diazepam blocked this cocaine
239 effect. No significant difference was observed between the group that received
240 cocaine+diazepam and the group that received saline+vehicle ($p = 0.99$). In addition, no
241 significant difference was observed between the group that received cocaine+diazepam and
242 the group that received saline+diazepam ($p=0.49$, Figure 2b).

243 We also tested the effects of cocaine and diazepam on four subtypes of USV calls: flat, step,
244 trill and mix (Figure 2c). Cocaine-treated rats presented higher numbers of all call subtypes
245 ($p < 0.01$) compared with the saline+vehicle group. Diazepam blocked the cocaine effect on
246 flat, trill and mix, subtypes: the number of calls emitted by the rats that received diazepam
247 and cocaine was significantly different compared to the rats that received cocaine. In
248 addition, the number of flat, trill and mix 50 kHz USV emitted by the cocaine+diazepam
249 group was not significantly different compared to the saline+vehicle group ($P = 0.98$). The
250 effect of diazepam on the step calls was less clear. The result suggests that diazepam
251 attenuated the effect of cocaine because the number of step calls of the cocaine group, but
252 not of the cocaine+diazepam group, was significantly different compared to the
253 saline+vehicle group ($p < 0.05$). However, the number of step calls in the cocaine+diazepam
254 group was not significantly different compared to the cocaine group (Figure 2d). Figure 3a

255 shows that the saline+vehicle and saline+diazepam groups emitted 50 kHz USV mainly in the
256 first 5 min and only few calls during the rest of the session. The animals of the
257 cocaine+vehicle group presented a different distribution; they emitted calls throughout all
258 the test session with a decay in call number across time. In contrast, animals treated with
259 both diazepam and cocaine presented a similar pattern of call distribution as the
260 saline+diazepam and saline+vehicle groups. One-way ANOVA showed that neither
261 diazepam, cocaine, nor their combination had an effect on call duration (Figure 3b, $F_{3,36} =$
262 0.495, $p = 0.69$) and call frequency (Figure 3c, $F_{3,36} = 0.88$, $p = 0.46$).

263 **3.3 Diazepam decreases locomotor activity produced by cocaine**

264 Locomotor activity (travelled distance) was measured in the same baseline and test sessions
265 in which USV were recorded (Figure 4). A repeated measures ANOVA showed a significant
266 session factor ($F_{1,16} = 30.18$, $p < 0.001$), a significant group factor ($F_{3,36} = 38.86$, $p < 0.001$) and
267 a significant session x group interaction ($F_{3,36} = 40.3$, $p < 0.001$). We used Tukey test in all
268 post-hoc comparisons among groups. No significant difference among groups was observed
269 on the baseline day ($P > 0.99$, data not shown). Only rats that received cocaine on the test
270 day travelled longer distances compared to the same group on the baseline day and
271 compared to all other groups on the test day ($p < 0.05$). As shown in Figure 4a, on the test
272 day both the group treated with cocaine and the group treated with cocaine+diazepam
273 travelled longer distances compared to the saline+vehicle group ($p < 0.05$). However, the
274 distance traveled by the cocaine+diazepam group was significantly shorten compared to the
275 cocaine group ($p < 0.05$). This finding suggests that diazepam blocked partly, but not
276 completely, the stimulant cocaine effect on locomotion. Representative path tracks are
277 shown in Figure 4b. Figure 4c shows the average distance traveled by rats during the 40 min
278 of the test sessions divided into 5-minute bins. Note that while the locomotor activity of the
279 control group decreased 5 min after the start of the test session, the locomotor activity of
280 the rats treated with cocaine increased at that time and this increase was maintained for
281 the rest of the session. Note also that the co-administration of diazepam attenuated this
282 locomotor stimulant effect of cocaine during the 40 min of the test session.

283 **4 DISCUSSION**

284 To evaluate the potential of benzodiazepines to treat stimulant drug disorders, it is
285 important to determine whether benzodiazepines can counteract the neurochemical and
286 behavioral effects of a stimulant drug. It have previously been shown that diazepam can
287 attenuate the effects of amphetamine on NAc dopamine release, measured by FSCV and
288 microdialysis (Zetterström and Fillenz, 1990; Murai et al., 1994; Gomez-A et al., 2017). In
289 another study, we showed that diazepam can also attenuate the effects of amphetamine on
290 rat 50 kHz USV and stereotyped behavior (Guaita et al., 2018). In the present study, we used
291 FSCV to show that systemic injection of diazepam not only decreases dopamine release, but
292 also reverts the increase in dopamine release in the NAc caused by cocaine in rats.
293 Additionally, we showed that diazepam blocked the increase in the emissions of 50 kHz USV
294 calls and attenuated the increase in locomotor activity caused by cocaine in rats. Together,
295 these data indicate that benzodiazepines can blunt multiple key effects of acute stimulants.

296 In the present study we also tested the effect of diazepam on cocaine-evoked 50 KHz USV, a
297 rat model of the rewarding effect of stimulant drugs. Rats emit 50 KHz USV in response to
298 rewarding stimuli (Burgdorf et al., 2008; Brenes and Schwarting, 2015; Brenes et al., 2016;
299 Wendler et al., 2016a; Engelhardt et al., 2017; Simola and Brudzynski, 2018) and in response
300 to reward-predictive stimuli (Brenes and Schwarting, 2015). Dopamine is released in the
301 NAc in response to the same stimuli (Ikemoto et al., 2015; Vega-Villar et al., 2019). Likewise,
302 rats vocalize at 50-kHz USV when challenged with cocaine (Barker et al., 2010; Browning et
303 al., 2011), amphetamine (Burgdorf et al., 2001; Pereira et al., 2014; Wöhr et al., 2015;
304 Guaita et al., 2018), and other stimulant drugs (Simola et al., 2012b; Wendler et al., 2016b;
305 Simola and Brudzynski, 2018). Furthermore, rat 50 kHz USV can be elicited by dopamine
306 receptor agonists (Brudzynski et al., 2012), and stimulation of the VTA (Scardocho et al.,
307 2015). Conversely, 50-kHz USV are reduced by VTA lesions and by dopamine receptor
308 antagonists (Burgdorf et al., 2007; Ringel et al., 2013; Brudzynski, 2015; Rippberger et al.,
309 2015).

310 When an individual self-administers stimulant drugs, the self-administration behavior that
311 preceded the drug-induced dopamine release is reinforced. This self-sustained cycle is
312 thought to play a key role in drug addiction. Furthermore, because these drugs cause
313 dopamine release, the stimuli that were paired with the drug acquire incentive salience.

314 Over time, stimuli that became predictive of drug effects acquire the property to cause
315 dopamine release in the striatum, which increases the motivation (wanting) that acts as an
316 incentive for drug-seeking and drug consumption (Volkow et al., 2017). In agreement with
317 this hypothesis, it has been shown that rats responded to a cue that precedes access to
318 cocaine by exhibiting 50-kHz USV and that the number of calls were exacerbated when rats
319 were abstinent (Maier et al., 2010). Therefore, the finding that diazepam blocks the effects
320 of cocaine on dopamine release, 50-kHz USV, and locomotor activity in rats suggests that it
321 may also be effective to attenuate the reinforcing, cue-evoked craving, and psychostimulant
322 effects of cocaine in humans.

323 According the 2020 UNODOC World Drug Report informs 65 million people in the world
324 consume stimulant drugs. Therefore, it is crucial to find putative drugs to treat stimulant
325 use. The results of the present study suggest that GABA_A-R positive modulators such as
326 benzodiazepines are promising drugs to attain this need.

327 **ACKNOWLEDGEMENTS**

328 We thank Delegado Víctor A. Lopez from the Superintendência da Polícia Federal of
329 Paranaguá for the donation of cocaine and Dr. Guilherme L. Sasaki for determining cocaine
330 purity. We also thank Dr. Alexander Gómez-A for assistance with statistical analysis of the
331 electrochemical data and Dr. Charles Blaha for the use the MINCS and WINCS
332 instrumentation for FSCV experiments. This study was financed in part by the Coordination
333 for the Improvement of Higher Education Personnel – Brazil (CAPES, PROBRAL GRANT
334 88881.198683/2018-01) and by The Brazilian National Council for Scientific and
335 Technological Development (CNPq, grants 432061/2018-5, 306855/2017-8, 465346/2014-
336 60, and: 312201/2019-2), The Brazilian Financier of Studies and Projects (FINEP, grant
337 01.19.0153-00), Deutsche Forschungsgemeinschaft (DFG, SCHW 559/15-1); Deutscher
338 Akademischer Austauschdienst (DAAD, 57446778).

339 **AUTHOR CONTRIBUTIONS**

340 CDC conceived the project, acquired funding, planned the FSCV experimental design with
341 DLR and WNS and the USV experimental design with RA and RKS. WSL performed the FSCV
342 experiments and analysis with CDC and DLR. WSL also performed the USV experiments and

343 analysis with ME. The histology and electrode preparation were done by LFJ. The analysis of
344 locomotion was performed by JAP. All authors discussed the results. The manuscript was
345 written by WNS and CDC. All authors commented on the manuscript.

346 **CONFLICT OF INTEREST**

347 The authors declare no conflicts of interest.

348 **DECLARATION OF TRANSPARENCY AND SCIENTIFIC RIGOUR**

349 This Declaration acknowledges that this paper adheres to the principles for transparent
350 reporting and scientific rigour of preclinical research as stated in the BJP guidelines for
351 Design & Analysis and Animal Experimentation, and as recommended by funding agencies,
352 publishers, and other organizations engaged with supporting research.

353 **ORCID**

354 *William N. Sanchez* <https://orcid.org/0000-0001-7723-0064>

355 *Jose A. Pochapski* <https://orcid.org/0000-0002-2331-4702>

356 *Rainer K. Schwarting* <https://orcid.org/0000-0002-4686-3974>

357 *Donita L. Robinson* <https://orcid.org/0000-0001-7540-3363>

358 *Roberto Andreatini* <https://orcid.org/0000-0002-8661-9132>

359 *Claudio da Cunha* <https://orcid.org/0000-0001-6920-8561>

360 **FIGURE LEGENDS**

361 **FIGURE 1** Diazepam blocks cocaine effect on dopamine release in the NAc evoked by
362 electrical stimulation of the VTA. **a.** Experiment design, **b.** Schematic drawing for electrode
363 implantation; red dots indicate electrode implantation for animals treated with cocaine and
364 dark blue dots indicate electrode implantation in cocaine + diazepam group, **c.** Average
365 results of diazepam effect on NAc Da release in rats treated with saline+vehicle (n=8),
366 cocaine+vehicle (n= 7) and cocaine+diazepam (n= 7) recorded every 5 min for 105 min (left)
367 and 25 min bins (right). Shading indicates \pm SEM. Data were analyzed with GLM Poisson
368 regression with post hoc Tukey tests. Means with different letters are significantly different
369 from each other ($p < 0.05$), and means with the same letter are not significantly different. **d.**
370 Representative examples taken from an individual rat of background-subtracted cyclic
371 voltammograms and color plots of the diazepam effect. In voltammograms and color plots,
372 the dotted line indicates maximum current potential (0.75 V); note the difference in current
373 scale for the voltammograms. For color plots, the red bar indicates five seconds and the
374 white arrow indicates the stimulation time.

375

376 **FIGURE 2** Diazepam blocked the cocaine-induced 50-kHz USV. **a.** Experimental design. **b.**
377 Diazepam effect on total 50-kHz calls on the test. **c.** Examples of USV call type. **d.** Call
378 subtypes on the test day (flat: upper left, step: upper right, trill: lower left, mix: lower right).
379 * $p < 0.05$ compared to the Sal/Veh group, # $p < 0.05$, compared to the Sal/Diaz group, & $p <$
380 0.05 compared to the Coc/Diaz group, Tukey test after two-way ANOVA. Sal/Veh (n=10),
381 Sal/Diaz (n=10), Coc/Veh (n=11), Coc/Diaz (n=9). Coc, $20 \text{ mg}\cdot\text{kg}^{-1}$ cocaine; Diaz, $2.5 \text{ mg}\cdot\text{kg}^{-1}$
382 diazepam, Sal, saline (cocaine's vehicle), Veh, diazepam's vehicle.

383

384 **FIGURE 3** Time course and acoustic parameters of the cocaine and diazepam effects on
385 appetitive 50-kHz USV. Sal/Veh (n=10), Sal/Diaz (n=10), Coc/Veh (n=11), Coc/Diaz (n=9). Coc,
386 $20 \text{ mg}\cdot\text{kg}^{-1}$ cocaine; Diaz, $2.5 \text{ mg}\cdot\text{kg}^{-1}$ diazepam Sal, saline (cocaine's vehicle), Veh,
387 diazepam's vehicle.

388

389 **FIGURE 4.** Diazepam attenuates the cocaine effect on locomotion activity. **a.** Travelled
390 distance during the 40 min session. **b.** Representative individual pathways of locomotion for
391 baseline and test day. **c.** Travelled distance in 5-min intervals. + $p < 0.05$ compared to the
392 same group on the baseline day; * $p < 0.05$, compared to saline vehicle in the test day; # $p <$
393 0.05 , compared to saline+diazepam on the test day; & $p < 0.05$ compared to
394 cocaine+diazepam on the test day, Tukey test after ANOVA. Coc, $20 \text{ mg}\cdot\text{kg}^{-1}$ cocaine; Diaz,
395 $2.5 \text{ mg}\cdot\text{kg}^{-1}$ diazepam; Sal, cocaine vehicle (saline); Veh, diazepam vehicle.

396 **REFERENCES**

- 397 Augier, E., Vouillac, C., and Ahmed, S.H. (2012). Diazepam promotes choice of abstinence in
398 cocaine self-administering rats. *Addict. Biol.* *17*: 378–391.
- 399 Barker, D.J., Root, D.H., Ma, S., Jha, S., Megehee, L., Pawlak, A.P., et al. (2010). Dose-
400 dependent differences in short ultrasonic vocalizations emitted by rats during cocaine self-
401 administration. *Psychopharmacology (Berl)*. *211*: 435–442.
- 402 Brenes, J.C., Lackinger, M., Höglinger, G.U., Schratt, G., Schwarting, R.K.W., and Wöhr, M.
403 (2016). Differential effects of social and physical environmental enrichment on brain
404 plasticity, cognition, and ultrasonic communication in rats. *J. Comp. Neurol.* *524*: 1586–
405 1607.
- 406 Brenes, J.C., and Schwarting, R.K.W. (2015). Individual differences in anticipatory activity to
407 food rewards predict cue-induced appetitive 50-kHz calls in rats. *Physiol. Behav.* *149*: 107–
408 118.
- 409 Browning, J.R., Browning, D.A., Maxwell, A.O., Dong, Y., Jansen, H.T., Panksepp, J., et al.
410 (2011). Positive affective vocalizations during cocaine and sucrose self-administration: A
411 model for spontaneous drug desire in rats. *Neuropharmacology* *61*: 268–275.
- 412 Brudzynski, S. (2015). Pharmacology of ultrasonic vocalizations in adult rats: significance, call
413 classification and neural substrate. *Curr. Neuropharmacol.* *13*: 180–192.
- 414 Brudzynski, S.M., Komadoski, M., and Pierre, J. St. (2012). Quinpirole-induced 50kHz
415 ultrasonic vocalization in the rat: Role of D2 and D3 dopamine receptors. *Behav. Brain Res.*
416 *226*: 511–518.
- 417 Burgdorf, J., Knutson, B., Panksepp, J., and Ikemoto, S. (2001). Nucleus accumbens
418 amphetamine microinjections unconditionally elicit 50-kHz ultrasonic vocalizations in rats.
419 *Behav. Neurosci.* *115*: 940–944.
- 420 Burgdorf, J., Kroes, R.A., Moskal, J.R., Pfaus, J.G., Brudzynski, S.M., and Panksepp, J. (2008).
421 Ultrasonic vocalizations of rats (*Rattus norvegicus*) during mating, play, and aggression:
422 behavioral concomitants, relationship to reward, and self-administration of playback. *J.*


- 423 Comp. Psychol. *122*: 357–367.
- 424 Burgdorf, J., Wood, P.L., Kroes, R.A., Moskal, J.R., and Panksepp, J. (2007). Neurobiology of
425 50-kHz ultrasonic vocalizations in rats: Electrode mapping, lesion, and pharmacology
426 studies. *Behav. Brain Res.* *182*: 274–283.
- 427 Calcaterra, N.E., and Barrow, J.C. (2014). Classics in chemical neuroscience: Diazepam
428 (valium). *ACS Chem. Neurosci.* *5*: 253–260.
- 429 Church, W.H., Justice, J.B., and Byrd, L.D. (1987). Extracellular dopamine in rat striatum
430 following uptake inhibition by cocaine, nomifensine and benztropine. *Eur. J. Pharmacol.* *139*:
431 345–348.
- 432 Coffey, K.R., Marx, R.G., and Neumaier, J.F. (2019). DeepSqueak: a deep learning-based
433 system for detection and analysis of ultrasonic vocalizations. *Neuropsychopharmacology* *44*:
434 859–868.
- 435 Engelhardt, K.A., Fuchs, E., Schwarting, R.K.W., and Wöhr, M. (2017). Effects of
436 amphetamine on pro-social ultrasonic communication in juvenile rats: Implications for
437 mania models. *Eur. Neuropsychopharmacol.* *27*: 261–273.
- 438 Farrell, M., Martin, N.K., Stockings, E., Bórquez, A., Cepeda, J.A., Degenhardt, L., et al.
439 (2019). Responding to global stimulant use: challenges and opportunities. *Lancet* *394*: 1652–
440 1667.
- 441 Garris, P.A., Christensen, J.R.C., Rebec, G. V., and Wightman, R.M. (2002). Real-Time
442 Measurement of Electrically Evoked Extracellular Dopamine in the Striatum of Freely
443 Moving Rats. *J. Neurochem.* *68*: 152–161.
- 444 Garris, P.A., and Wightman, R.M. (1995). Distinct pharmacological regulation of evoked
445 dopamine efflux in the amygdala and striatum of the rat in vivo. *Synapse* *20*: 269–279.
- 446 German, C.L., Baladi, M.G., McFadden, L.M., Hanson, G.R., and Fleckenstein, A.E. (2015).
447 Regulation of the dopamine and vesicular monoamine transporters: Pharmacological targets
448 and implications for disease. *Pharmacol. Rev.* *67*: 1005–1024.

- 449 Gomez-A, A., Fiorenza, A.M., Boschen, S.L., Sugi, A.H., Beckman, D., Ferreira, S.T., et al.
450 (2017). Diazepam inhibits electrically evoked and tonic dopamine release in the nucleus
451 accumbens and reverses the effect of amphetamine. *ACS Chem. Neurosci.* *8*: 300–309.
- 452 Guaita, G., Vecchia, D.D., Andreatini, R., Robinson, D.L., Schwarting, R.K.W., and Cunha, C.
453 Da (2018). Diazepam blocks 50 kHz ultrasonic vocalizations and stereotypies but not the
454 increase in locomotor activity induced in rats by amphetamine. *Psychopharmacology (Berl).*
455 *235*: 1887–1896.
- 456 Hall, F.S., Li, X.F., Randall-Thompson, J., Sora, I., Murphy, D.L., Lesch, K.P., et al. (2009).
457 Cocaine-conditioned locomotion in dopamine transporter, norepinephrine transporter and
458 5-HT transporter knockout mice. *Neuroscience* *162*: 870–880.
- 459 Heien, M.L.A.V., Khan, A.S., Ariansen, J.L., Cheer, J.F., Phillips, P.E.M., Wassum, K.M., et al.
460 (2005). Real-time measurement of dopamine fluctuations after cocaine in the brain of
461 behaving rats. *Proc. Natl. Acad. Sci. U. S. A.* *102*: 10023–10028.
- 462 Hernandez, L., and Hoebel, B.G. (1988). Food reward and cocaine increase extracellular
463 dopamine in the nucleus accumbens as measured by microdialysis. *Life Sci.* *42*: 1705–1712.
- 464 Ikemoto, S., Yang, C., and Tan, A. (2015). Basal ganglia circuit loops, dopamine and
465 motivation: A review and enquiry. *Behav. Brain Res.* *290*: 17–31.
- 466 Kampman, K.M. (2019). The treatment of cocaine use disorder. *Sci. Adv.* *5*: 1–9.
- 467 Maier, E.Y., Ahrens, A.M., Ma, S.T., Schallert, T., and Duvauchelle, C.L. (2010). Cocaine
468 deprivation effect: Cue abstinence over weekends boosts anticipatory 50-kHz ultrasonic
469 vocalizations in rats. *Behav. Brain Res.* *214*: 75–79.
- 470 Masiulis, S., Desai, R., Uchański, T., Serna Martin, I., Laverty, D., Karia, D., et al. (2019).
471 GABAA receptor signalling mechanisms revealed by structural pharmacology. *Nature* *565*:
472 454–459.
- 473 Murai, T., Koshikawa, N., Kanayama, T., Takada, K., Tomiyama, K., and Kobayashi, M. (1994).
474 Opposite effects of midazolam and β -carboline-3-carboxylate ethyl ester on the release of
475 dopamine from rat nucleus accumbens measured by in vivo mudialysis. *Eur. J. Pharmacol.*

- 476 261: 65–71.
- 477 Panhelainen, A.E., Vekovischeva, O.Y., Aitta-aho, T., Rasanen, I., Ojanperä, I., and Korpi, E.R.
478 (2011). Diazepam-induced neuronal plasticity attenuates locomotor responses to morphine
479 and amphetamine challenges in mice. *Neuroscience* 192: 312–321.
- 480 Paxinos, G., and Watson, C. (1998). *The Rat Brain in Stereotaxic Coordinates* (San Diego:
481 Academic Press).
- 482 Pereira, M., Andreatini, R., Schwarting, R.K.W., and Brenes, J.C. (2014). Amphetamine-
483 induced appetitive 50-kHz calls in rats: A marker of affect in mania? *Psychopharmacology*
484 (Berl). 231: 2567–2577.
- 485 Phillips, P.E.M., Stuber, G.D., Helen, M.L.A.V., Wightman, R.M., and Carelli, R.M. (2003).
486 Subsecond dopamine release promotes cocaine seeking. *Nature* 422: 614–618.
- 487 Ringel, L.E., Basken, J.N., Grant, L.M., and Ciucci, M.R. (2013). Dopamine D1 and D2 receptor
488 antagonism effects on rat ultrasonic vocalizations. *Behav. Brain Res.* 252: 252–259.
- 489 Rippberger, H., Gaalen, M. van, Schwarting, R., and Wöhr, M. (2015). Environmental and
490 pharmacological modulation of amphetamine- induced 50-kHz Ultrasonic Vocalizations in
491 rats. *Curr. Neuropharmacol.* 13: 220–232.
- 492 Sabeti, J., Gerhardt, G.A., and Zahniser, N.R. (2003). Chloral hydrate and ethanol, but not
493 urethane, alter the clearance of exogenous dopamine recorded by chronoamperometry in
494 striatum of unrestrained rats. *Neurosci. Lett.* 343: 9–12.
- 495 Scardocho, T., Trujillo-Pisanty, I., Conover, K., Shizgal, P., and Clarke, P.B.S. (2015). The
496 effects of electrical and optical stimulation of midbrain dopaminergic neurons on rat 50-kHz
497 ultrasonic vocalizations. *Front. Behav. Neurosci.* 9: 1–15.
- 498 Simola, N., and Brudzynski, S.M. (2018). Rat 50-kHz ultrasonic vocalizations as a tool in
499 studying neurochemical mechanisms that regulate positive emotional states. *J. Neurosci.*
500 *Methods* 310: 33–44.
- 501 Simola, N., Fenu, S., Costa, G., Pinna, A., Plumitallo, A., and Morelli, M. (2012a).

- 502 Pharmacological characterization of 50-kHz ultrasonic vocalizations in rats: Comparison of
503 the effects of different psychoactive drugs and relevance in drug-induced reward.
504 *Neuropharmacology* 63: 224–234.
- 505 Simola, N., Fenu, S., Costa, G., Pinna, A., Plumitallo, A., and Morelli, M. (2012b).
506 Pharmacological characterization of 50-kHz ultrasonic vocalizations in rats: Comparison of
507 the effects of different psychoactive drugs and relevance in drug-induced reward.
508 *Neuropharmacology* 63: 224–234.
- 509 Simola, N., Frau, L., Plumitallo, A., and Morelli, M. (2014). Direct and long-lasting effects
510 elicited by repeated drug administration on 50-kHz ultrasonic vocalizations are regulated
511 differently: Implications for the study of the affective properties of drugs of abuse. *Int. J.*
512 *Neuropsychopharmacol.* 17: 429–441.
- 513 Tilley, M.R., Cagniard, B., Zhuang, X., Han, D.D., Tiao, N., and Gu, H.H. (2007). Cocaine
514 reward and locomotion stimulation in mice with reduced dopamine transporter expression.
515 *BMC Neurosci.* 8: 1–7.
- 516 Uusi-oukari, M., and Korpi, E.R. (2010). Regulation of GABA A receptor subunit expression by
517 pharmacological agents. *Pharmacol. Rev.* 62: 97–135.
- 518 Vega-Villar, M., Horvitz, J.C., and Nicola, S.M. (2019). NMDA receptor-dependent plasticity
519 in the nucleus accumbens connects reward-predictive cues to approach responses. *Nat.*
520 *Commun.* 10:.
- 521 Volkow, N.D., Wise, R.A., and Baler, R. (2017). The dopamine motive system: Implications
522 for drug and food addiction. *Nat. Rev. Neurosci.* 18: 741–752.
- 523 Wang, K.H., Penmatsa, A., and Gouaux, E. (2015). Neurotransmitter and psychostimulant
524 recognition by the dopamine transporter. *Nature* 521: 322–327.
- 525 Wendler, E., Souza, C.P. de, Vecchia, D.D., Kanazawa, L.K.S., Almeida Soares Hocayen, P. de,
526 Wöhr, M., et al. (2016a). Evaluation of 50-kHz ultrasonic vocalizations in animal models of
527 mania: Ketamine and lisdexamfetamine-induced hyperlocomotion in rats. *Eur.*
528 *Neuropsychopharmacol.* 26: 1900–1908.

- 529 Wendler, E., Souza, C.P. de, Vecchia, D.D., Kanazawa, L.K.S., Almeida Soares Hocayen, P. de,
530 Wöhr, M., et al. (2016b). Evaluation of 50-kHz ultrasonic vocalizations in animal models of
531 mania: Ketamine and lisdexamfetamine-induced hyperlocomotion in rats. *Eur.*
532 *Neuropsychopharmacol.* 26: 1900–1908.
- 533 Wöhr, M., Rippberger, H., Schwarting, R.K.W., and Gaalen, M.M. Van (2015). Critical
534 involvement of 5-HT_{2C} receptor function in amphetamine-induced 50-kHz ultrasonic
535 vocalizations in rats. *Psychopharmacology (Berl)*. 232: 1817–1829.
- 536 Zetterström, T., and Fillenz, M. (1990). Local administration of flurazepam has different
537 effects on dopamine release in striatum and nucleus accumbens: A microdialysis study.
538 *Neuropharmacology* 29: 129–134.
- 539 Zhu, S., Noviello, C.M., Teng, J., Walsh, R.M., Kim, J.J., and Hibbs, R.E. (2018). Structure of a
540 human synaptic GABAA receptor. *Nature* 559: 67–88.






Figure 2







a**# of calls****b****c**

Figure 3






Figure 4